TrialCurveECHELON-2 (5-year update): reconstructed Kaplan–Meier curves
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Ann Oncol. Author manuscript; Available in PMC 2022 Sep 6. |
|---|---|
| DOI | 10.1016/j.annonc.2021.12.002 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival per investigator — Intent-to-treat population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: A+CHP 62.2 months; CHOP 23.8 months. Survival at 18 months: A+CHP 67%; CHOP 54%. Hazard ratio A+CHP vs CHOP 0.69 (95% CI 0.52–0.90).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| A+CHP | 226 | 94 | 62.2 |
| CHOP | 226 | 125 | 23.8 |
- A+CHP vs CHOP: reconstructed HR 0.69 (95% CI 0.52–0.90)
Landmark survival (reconstructed)
| Time | A+CHP | CHOP |
|---|---|---|
| 6 mo | 83.6% | 71.8% |
| 12 mo | 71.4% | 57.8% |
| 18 mo | 66.6% | 53.7% |
| 24 mo | 63.6% | 49.4% |
| 36 mo | 59.3% | 46.9% |
| 48 mo | 56.1% | 46.3% |
| 60 mo | 51.6% | 42.9% |
Checks against the published figure
- A+CHP median: printed 62.3, reconstructed 62.2 pass
- CHOP median: printed 23.8, reconstructed 23.8 pass
- A+CHP events: printed 94, reconstructed 94 pass
- A+CHP n: printed 226, reconstructed 226 pass
- CHOP events: printed 125, reconstructed 125 pass
- CHOP n: printed 226, reconstructed 226 pass
- hazard ratio: printed 0.7, reconstructed 0.685 pass
Progression-free survival per investigator — Patients with systemic anaplastic large cell lymphoma (sALCL)
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: A+CHP not reached; CHOP 53.7 months. Survival at 18 months: A+CHP 73%; CHOP 57%. Hazard ratio A+CHP vs CHOP 0.57 (95% CI 0.40–0.81).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| A+CHP | 162 | 52 | not reached |
| CHOP | 154 | 77 | 53.7 |
- A+CHP vs CHOP: reconstructed HR 0.57 (95% CI 0.40–0.81)
Landmark survival (reconstructed)
| Time | A+CHP | CHOP |
|---|---|---|
| 6 mo | 88.6% | 68.5% |
| 12 mo | 78.1% | 59.2% |
| 18 mo | 72.7% | 56.5% |
| 24 mo | 69.9% | 54.4% |
| 36 mo | 68.4% | 51.4% |
| 48 mo | 64.1% | 50.4% |
| 60 mo | 61.0% | 48.6% |
Checks against the published figure
- CHOP median: printed 54.2, reconstructed 53.7 pass
- A+CHP events: printed 53, reconstructed 52 pass
- A+CHP n: printed 162, reconstructed 162 pass
- CHOP events: printed 77, reconstructed 77 pass
- CHOP n: printed 154, reconstructed 154 pass
- hazard ratio: printed 0.55, reconstructed 0.572 pass
Overall survival — Intent-to-treat population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: A+CHP not reached; CHOP not reached. Survival at 18 months: A+CHP 85%; CHOP 74%. Hazard ratio CHOP vs A+CHP 1.38 (95% CI 1.00–1.90).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| A+CHP | 226 | 67 | not reached |
| CHOP | 226 | 89 | not reached |
- CHOP vs A+CHP: reconstructed HR 1.38 (95% CI 1.00–1.90)
Landmark survival (reconstructed)
| Time | A+CHP | CHOP |
|---|---|---|
| 6 mo | 93.8% | 89.2% |
| 12 mo | 87.9% | 82.4% |
| 18 mo | 85.1% | 74.2% |
| 24 mo | 80.5% | 72.8% |
| 36 mo | 76.2% | 69.0% |
| 48 mo | 73.7% | 65.7% |
| 60 mo | 70.1% | 61.0% |
Checks against the published figure
- A+CHP events: printed 68, reconstructed 67 pass
- A+CHP n: printed 226, reconstructed 226 pass
- CHOP events: printed 89, reconstructed 89 pass
- CHOP n: printed 226, reconstructed 226 pass
- hazard ratio: printed 0.72, reconstructed 0.725 pass
Overall survival — Patients with systemic anaplastic large cell lymphoma (sALCL)
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: A+CHP not reached; CHOP not reached. Survival at 18 months: A+CHP 89%; CHOP 76%. Hazard ratio A+CHP vs CHOP 0.69 (95% CI 0.46–1.06).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| A+CHP | 162 | 39 | not reached |
| CHOP | 154 | 49 | not reached |
- A+CHP vs CHOP: reconstructed HR 0.69 (95% CI 0.46–1.06)
Landmark survival (reconstructed)
| Time | A+CHP | CHOP |
|---|---|---|
| 6 mo | 95.0% | 85.5% |
| 12 mo | 91.2% | 80.1% |
| 18 mo | 88.7% | 76.1% |
| 24 mo | 84.8% | 74.0% |
| 36 mo | 80.1% | 72.7% |
| 48 mo | 77.4% | 71.3% |
| 60 mo | 75.8% | 68.7% |
Checks against the published figure
- A+CHP events: printed 39, reconstructed 39 pass
- A+CHP n: printed 162, reconstructed 162 pass
- CHOP events: printed 49, reconstructed 49 pass
- CHOP n: printed 154, reconstructed 154 pass
- hazard ratio: printed 0.66, reconstructed 0.693 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/echelon-2-5-year-update-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/echelon-2-5-year-update-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Ann Oncol. Author manuscript; Available in PMC 2022 Sep 6. doi:10.1016/j.annonc.2021.12.002. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/echelon-2-5-year-update
Report a problem with these data
Related trials
- CLL14 (5-year update): Overall survival; Progression-free survival
- SUNMO (Japanese subgroup): Overall survival (interim analysis); Progression-free survival (centrally assessed, primar
- ENRICH: Overall survival; Progression-free survival
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- AGILE (long-term follow-up): Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials